Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + carboplatin + doxorubicin + cyclophosphamide + capecitabine
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination chemotherapy regimen consisting of five anticancer drugs used in the treatment of cancer, particularly breast cancer. Each component has a distinct mechanism of action: - Paclitaxel (Taxol): A taxane that damages the structure supporting cancer cells, preventing cell division - Carboplatin: A platinum agent that damages DNA in cancer cells - Doxorubicin (Adriamycin): An anthracycline that damages DNA inside cancer cells - Cyclophosphamide (Cytoxan): An alkylating agent that damages DNA in cancer cells during their resting phase - Capecitabine (Xeloda): An oral prodrug that converts to 5-fluorouracil in tumor tissue This intensive combination would likely be used in advanced or high-risk cancer cases where aggressive treatment is warranted.
- Other names
- Sequential paclitaxel/carboplatin followed by doxorubicin/cyclophosphamide/capecitabineRAMS neoadjuvant TNBC regimenSequential Chemotherapy for Locally Advanced TNBC
02
Targets
DNATOP2A (DNA topoisomerase II)TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + carboplatin + doxorubicin + cyclophosphamide + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + carboplatin + doxorubicin + cyclophosphamide + capecitabine.